Probenecid and Diethyldithiocarbamate as Modifiers of Cisplatin Toxicity

  • Charlotte Jacobs

Abstract

Cisplatin (CP) has proved to be the most important new chemotherapeutic agent in the last two decades. The clinical use of CP in treating cancer was initially severely limited by nephrotoxicity. With the use of hydration and mannitol diuresis, renal damage was minimized for CP used at standard doses (up to 100 mg/m2). Now long-term use of the drug in responding patients is limited by renal dysfunction in approximately 20% of patients. In attempting to expand the use of cisplatin with high doses, clinicians have found nephrotoxicity, as well as other toxicities, to be dose-limiting. At Stanford University, we have conducted trials to ameliorate toxicity through two different mechanisms of action: inhibition of platinum renal secretion in the kidney by probenecid and chelation of platinum with diethyldithiocarbamate (DDTC).

Keywords

Human Kidney Inulin Clearance Renal Handling Fractional Clearance Free Platinum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    D.C. Dobyan, J. Levi, C. Jacobs, J. Kosek, and M.W. Weiner, Mechanism of cis-platinum nephrotoxicity: 11. Morphologic observations, J Pharmacol Exp Ther. 213:551 (1980).PubMedGoogle Scholar
  2. 2.
    J. Levi, C. Jacobs, S.M. Kaiman, M. McTigue, and M.W. Weiner, Mechanism of cis-platinum nephrotoxicity: 1. Effects of sulfhydryl groups in rat kidneys, J Pharmacol Exp Ther. 213:545 (1980).PubMedGoogle Scholar
  3. 3.
    M.W. Weiner, and C. Jacobs, Mechanism of cisplatin nephrotoxicity, Fed Proc. 42:2974 (1983).PubMedGoogle Scholar
  4. 4.
    C. Jacobs, S. Kaiman, M. Tretton, and M.W. Weiner, Renal handling of cis-diamminedichloroplatinum (11), Cancer Treat Rep. 64:1223 (1980).PubMedGoogle Scholar
  5. 5.
    C. Jacobs, C. Coleman, L. Rich, K. Hirst, and M.W. Weiner, Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid, Cancer Res. 44:3662 (1984).Google Scholar
  6. 6.
    D.A. Ross, and G.R. Gale, Reduction of renal toxicity of cisdichlorodiammine platinum (II) by probenecid, Cancer Treat Rep. 63:781 (1979).PubMedGoogle Scholar
  7. 7.
    C. Jacobs, S. Kaubisch, J. Halsey, B.L. Lum, M. Gosland, C.N. Coleman, and B.I. Sikic, The use of probenecid as a chemoprotector against cisplatin nephrotoxicity, Cancer (in press).Google Scholar
  8. 8.
    R.F. Borch, J.C. Katz, P.H. Leider, et al, Effect of diethyldithiocarbamate rescue on tumor response to cisplatin in a rat model, Proc Natl Acad Sci USA. 77:5441 (1980).PubMedCrossRefGoogle Scholar
  9. 9.
    D.L. Bodenner, P.C. Dedon, P.C. Keng, et al, Selective protection against cis-diammine dichloroplatinum (11)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate, Cancer Res. 46:1585 (1986).Google Scholar
  10. 10.
    J.M. Berry, C. Jacobs, B. Sikic, J. Halsey, and R.F. Borch, Modification of cisplatin toxicity with diethyldithiocarbamate, J Clin Oncol 8:1585 (1990).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Charlotte Jacobs
    • 1
  1. 1.School of MedicineStanford UniversityStanfordUSA

Personalised recommendations